Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report

Combined radioimmunotherapy is currently being investigated to treat patients with cancer. Anti-programmed cell death-1 (PD-1) immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of tumo...

Full description

Saved in:
Bibliographic Details
Main Authors: Deepak Kumar, Said Dermime, Maysaloun Merhi, Afsheen Raza, Varghese Philipose Inchakalody, Kodappully S Siveen, Fairooz Sahir, Sarra Mestiri, Shereena Hydrose, Niloofar Allahverdi, Munir Jalis, Allan Relecom, Lobna Al Zaidan, Mohamed Sir Elkhatim Hamid, Mai Mostafa, Abdul Rehman Zar Gul, Shahab Uddin, Mohammed Al Homsi
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001278.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001278.full

Similar Items